Menarini shows Big Pharma how it's done with first approval for oral SERD drug in breast cancer

Italian drugmaker Menarini has succeeded where European Big Pharmas have failed, pushing the first oral selective estrogen receptor degrader (SERD) to treat breast cancer across the FDA finish line.